title: Sleep apnoea syndromes and the cardiovascular system.
abstract: Management of SAS and cardiovascular disease risk should be closely linked. It is important to screen for cardiovascular disease risk in patients with SAS and vice versa. CSA/CSR may be improved by ventilation strategies in heart failure, but benefit remains to be proven. For OSA, although CPAP may reduce cardiovascular disease risk, its main benefit is symptom control. In the longer-term, CPAP should be used alongside standard cardiovascular risk reduction strategies including robust weight management programmes, with referral for bariatric surgery in appropriate cases. CPAP and NIV should be considered for acute admissions with decompensated cardiac failure.
authors: Somerset Lung Centre, Taunton and Somerset NHS Foundation Trust. justin.pepperell@tst.nhs.uk
authors: Justin C
authors: JC
authors: Pepperell
mesh_terms: D001145:Arrhythmias, Cardiac / Q000150:complications; D002318:Cardiovascular Diseases / Q000150:complications*; D045422:Continuous Positive Airway Pressure; D003324:Coronary Artery Disease / Q000150:complications; D006333:Heart Failure / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000150:complications; D010102:Oxygen Inhalation Therapy; D018570:Risk Assessment; D012307:Risk Factors; D012891:Sleep Apnea Syndromes / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D016896:Treatment Outcome